All In Biotech

Drug Trial Radar · NCT07083323

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

262

Planned (sponsor's estimate)

Start

Jul 22, 2025

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • HY05350 for injectionDrug

    HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.

  • HY05350 for injectionDrug

    HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, the occurrence of dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days).
  2. Part 1, Incidence of Treatment-Emergent Adverse Events (TEAE)Time frame: Up to 2 years.
  3. Part 2, Objective Response Rate (ORR)Time frame: Up to 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.